This respiratory sector and companies that are helping patients using smartphones is such a great place to Be. Technology will be disruptive and companies in the sector could be the next Resmed, Cochlear or Sirtex.
I for one know that an objective monitor for asthma will be as popular as a digital thermometer or as a blood pressure monitor is for heart patients or a glucose monitor is for diabetics.
So there are two in the sector worth watching - both do different things:
1. RAP is trying to diagnose respiratory conditions with credible large studies and pave the way for doctors to diagnose patients. A dedicated algorithm team at the cutting edge and a good following in the market!! With a great market cap even after the temporary pullback.
2. RSH has a objective measurement tool, backed by the leading thoracic professor in Bruce Thompson and with approvals due in Q1 2019.
Interesting to see the board memebers who have joined in the past several months - two ex- Cochlear and one from Sirtex with IR and corporate development experience.
The signs are clear for investors that this is the sector to be in. Do you own research and be rewarded in short order...
RAP Price at posting:
12.0¢ Sentiment: Hold Disclosure: Not Held
